Mice's muscles respond to a new weight-loss drug that simulates exercise
It can be a difficult yet gratifying journey to lose weight. Burpees and a good diet can both help you get there, but there is a third alternative that is typically disregarded as dangerous. tablets for losing weight. Although the FDA has approved several of these medicines, concerns have been raised about their potential negative effects.
Recently, University of Florida researchers announced that they had created a weight loss supplement that, when given to rats, mimicked exercise and caused weight loss. According to the experts, there haven't been any serious negative effects from the medication yet.
What it does
The investigation was carried out using mice as an animal model. In a press statement, the researchers detailed how the drug, named SLU-PP-332, tricked fat mice's muscles into thinking they were exercising more than they actually were, improving the animals' metabolism and causing them to shed pounds.
According to the study, the medicine improved the mice's endurance, enabling them to run 50% farther than before.
Thomas Burris, a professor of pharmacy at UF who oversaw the current research into the novel medicine, explained that it simply instructs skeletal muscle to undergo the same adaptations you see during endurance training.
The metabolism of mice treated with the medication, according to Burris, "turns to utilising fatty acids, which is quite similar to what people utilize when they are fasting or exercising. "And the animal weight starts to drop."
What sets it apart from other drugs?
SLU-PP-332 does not alter the patient's appetite, unlike earlier medications like Ozempic. Instead, the medication enhances the body's natural response to exercise. The metabolism is boosted. According to the press release, the medication causes the body to behave as though it is in marathon training, increasing energy expenditure and accelerating the body's burning of fat.
Burris continued, "This might be able to keep people healthier as they age."
In March of this year, the same scientists published a second study in which they described how SLU-PP-332 was created to increase metabolic activity. In that investigation, it was discovered that mice of normal weight were able to run 45% farther and for 70% longer than mice not given the medication.
In the US, obesity is a significant public health concern. Cancer, heart disease, and type 2 diabetes are just a few of the illnesses it can cause. Fat builds up in skeletal muscle as a result of obesity, which causes insulin resistance and a decrease in metabolic efficiency.
The team aims to screen for side effects in other animal models before beginning human trials.
Research summary:
Physical activity reduces the risk of early death from all causes by causing physiological changes. A number of disorders, such as obesity and the metabolic syndrome, may be successfully treated using pharmacological exercise mimics. In a previous article, we discussed the creation of SLU-PP-332, an ERRa, b, and g nuclear receptor agonist that turns on an acute aerobic training program. Here, we investigate the effects of this exercise mimic on animal models of metabolic syndrome and obesity. SLU-PP-332 was given to mice that had been made obese or ob/ob through diet, and the effects on various metabolic parameters were evaluated.
The injection of SLU-PP-332 mimics the effects of exercise on mice's overall metabolism, including elevated energy expenditure and fatty acid oxidation. Decreased fat mass accumulation coincided with these outcomes. Additionally, in models of metabolic syndrome, the ERR agonist successfully decreased obesity and enhanced insulin sensitivity. The metabolic syndrome and obesity may be effectively treated by pharmacologically activating ERR. Meaningful Statement By reducing fat accumulation in obese mouse models, the estrogen receptor-related orphan receptor (ERR) agonist SLU-PP-332 shows potential as a therapy to treat metabolic illnesses.